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Summary
In Firmicutes and related bacteria, ribosomal large
subunit protein L27 is encoded with a conserved
N-terminal extension that is removed to expose resi-
dues critical for ribosome function. Bacteria encod-
ing L27 with this N-terminal extension also encode a
sequence-specific cysteine protease, Prp, which car-
ries out this cleavage. In this work, we demonstrate
that L27 variants with an un-cleavable N-terminal
extension, or lacking the extension (pre-cleaved), are
unable to complement an L27 deletion in Staphylo-
coccus aureus. This indicates that N-terminal proc-
essing of L27 is not only essential but possibly has a
regulatory role. Prp represents a new clade of previ-
ously uncharacterized cysteine proteases, and the
dependence of S. aureus on L27 cleavage by Prp vali-
dates the enzyme as a target for potential antibiotic
development. To better understand the mechanism of
Prp activity, we analyzed Prp enzyme kinetics and
substrate preference using a fluorogenic peptide
cleavage assay. Molecular modeling and site-directed
mutagenesis implicate several residues around the
active site in catalysis and substrate binding, and
support a structural model in which rearrangement
of a flexible loop upon binding of the correct peptide
substrate is required for the active site to assume the
proper conformation. These findings lay the founda-
tion for the development of antimicrobials that target
this novel, essential pathway.
Introduction
Recently, the Centers for Disease Control evaluated the
current and impending risks posed by antibiotic-resistant
bacterial pathogens. Their prioritized list includes Clos-
tridium difficile as one of the most urgent threats and
vancomycin-resistant Enterococcus (VRE), methicillin-
resistant Staphylococcus aureus and drug-resistant
Streptococcus pneumoniae as existing serious threats
(CDC, 2014). It has become abundantly clear that con-
tinuous antibiotic development is of primary importance
to protect patients from emerging resistant bacterial
pathogens. Current antibiotic therapies are already of
limited utility, yet the novel drugs that are being devel-
oped are often ‘me too’ drugs that work via the same
mechanism as existing antimicrobials. To create unique
drugs, new therapeutic targets and new data on the
function of existing targets are needed.
The eubacterial ribosome has historically been a
major target for numerous antibiotics, including macro-
lides (e.g., erythromycin), lincosamides, oxazolidinones
and tetracylines, which work by blocking aminoacyl-
tRNA binding, preventing peptidyl transfer or causing
premature peptidyl-tRNA release (Tejedor and Ballesta,
1986; Auerbach et al., 2002; Colca et al., 2003; Yonath,
2005). Protein synthesis and ribosome formation remain
extremely important yet underdeveloped targets in the
resistant pathogens that are only distantly related to the
bacterial model organism Escherichia coli.
We recently discovered a novel site-specific protease
in S. aureus that plays a critical role in basic ribosomal
biology (Wall et al., 2015). This enzyme is also present
in all of the resistant pathogens in the CDC list above,
and provides an attractive new target for antibiotic devel-
opment. We demonstrated that ribosomal protein L27 in
Firmicutes such as S. aureus, as well as in several other
bacterial phyla, is encoded as a pro-protein with an
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N-terminal extension that is not present in E. coli. The
S. aureus L27 pro-protein undergoes a site-specific
cleavage event, sometime before or during ribosomal
assembly, to yield a mature protein with an N-terminus
equivalent to that found in E. coli L27 (Wall et al., 2015).
Failure to remove the N-terminal extension was hypothe-
sized to occlude critical L27 residues that stabilize A
and P-site tRNAs at the peptidyl transferase center
(PTC), the active site of the ribosome (Maguire et al.,
2005; Voorhees et al., 2009; Polikanov et al., 2014).
Removal of the N-terminal extension is carried out by
Prp, a site-specific cysteine protease that belongs to a
family of conserved proteins of previously unknown
function identified as DUF464. Structural analysis of
several DUF464 family members revealed a protein fold
unlike that of any other known peptidase, which has led
to the assignment of Prp as the representative member
of a new protein family, C108, in the MEROPS pepti-
dase database (Rawlings et al., 2014). A better under-
standing of the mechanism of substrate binding and
catalysis by this new family of proteases will be required
for the development of specific inhibitors. In this work,
we confirm that the activity of the Prp protease is essen-
tial in S. aureus. We further characterize the enzyme
using kinetics, structural modeling and site-directed
mutagenesis. These data provide a foundation for fur-
ther exploration of fundamental differences in ribosome
biogenesis in this group of bacteria and constitute an ini-
tial basis for the rational design of new antimicrobials
that target this essential cleavage step.
Results
L27 cleavage is essential in S. aureus
Previous work indicating that Prp and L27 are both
essential in S. aureus was conducted via antisense
RNA expression and transposon mutagenesis (Ji et al.,
2001; Chaudhuri et al., 2009). The interpretation of
these results is complicated by possible polar effects of
a transposon insertion in Prp that might lead to lack of
downstream L27 expression, or antisense RNA that
might also have polar effects or destabilize the entire
transcript, which also includes ribosomal protein L21.
In order to determine whether Prp cleavage of L27
was essential, it was necessary to examine mutants
with altered L27 cleavage in S. aureus. We have previ-
ously shown that overexpression of catalytically inactive
Prp that binds tightly to L27 is toxic (Wall et al., 2015).
However, overexpression of un-cleavable L27 had mini-
mal effects in a background that also expressed the
wild-type protein, so it remained an open question
whether the cleavage event was essential for S. aureus
growth. To address this question, a plasmid-based com-
plementation system was constructed that allowed a
switch between wild-type L27 and mutants that either
lacked the cleavage motif or had a modified ‘un-
cleavable’ motif. This experiment was performed as
depicted in the schematic in Fig. 1A.
In the presence of a plasmid that required IPTG to
produce L27 (pEW27), the native chromosomal copy
of the L27 gene (rpmA) was deleted by replacement
with a spectinomycin resistance cassette. The result-
ant strain was dependent on IPTG for survival, demon-
strating conclusively for the first time that L27 is
essential in S. aureus. A compatible plasmid was sub-
sequently introduced which encoded various alleles of
L27 under control of an arsenite-inducible promoter
(Liu et al., 2004). By replacing IPTG with arsenite in
the medium, the mutant form of L27 was expressed in
place of the wild-type copy, allowing examination of
the effect of the loss of regulated L27 cleavage on S.
aureus. Plasmid pEW72 expresses wild type S. aureus
Fig. 1. Complementation by plasmid-encoded L27.
A. Outline of the genetic elements employed in the complementation
scheme. (1) Plasmid that encodes S. aureus L27 under control of the
T7 promoter repressed by LacI (pEW27); (2) S. aureus host strain,
derived from strain SA187RI, which contains the T7 RNA polymerase
on an integrated plasmid and a spectinomycin resistance cassette in
place of the gene encoding L27; (3) a compatible plasmid (pEW72-75)
encoding L27 or mutants under control of an arsenite-inducible
promoter.
B. Growth of cells carrying pEW27 and the different arsenite-inducible
L27 mutants. Each L27 variant carried on the arsenite-inducible
plasmid is listed to the left of the array. The three columns are
photographs taken of the growth of bacterial cells spotted onto solid
culture media containing 1 mM IPTG, no inducer, or 5 mM NaAsO2,
as indicated.
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L27 in the presence of arsenite and it is able to com-
plement the L27 chromosomal deletion. There is no
leaky expression from either promoter; in the absence
of IPTG or arsenite, the strain does not grow (Fig. 1B).
Plasmids pEW73-75 express variant forms of arsenite-
inducible L27. Plasmid pEW73 expresses ‘pre-cleaved’
L27 (D 2-9), which is missing the N-terminal cleavage
motif, making it effectively equivalent to the ‘short’ E.
coli-like L27. We confirmed via Edman degradation
that there is loss of the N-terminal methionine (which
would occlude substrate stabilization residues ASKK),
resulting a protein identical to that found in mature S.
aureus ribosomes (Colca et al., 2003). Plasmid
pEW74 expresses L27 F8A-F9A, an un-cleavable Prp
recognition motif mutant (Wall et al., 2015). Plasmid
pEW75 expresses the same pre-cleaved L27 as
pEW73 and, in addition, the post-cleavage ‘released’
peptide MLKLNLQFF, expressed from the same pro-
moter but using a separate downstream RBS. The pur-
pose of pEW75 was to determine whether the
released peptide had some independent effect on
growth.
Strains carrying pEW27 and compatible plasmids with
the arsenite-inducible L27 variants were spotted onto
solid media containing 1mM IPTG, no inducer, or 5 mM
sodium arsenite. All grew on plates with IPTG, all failed
to grow without any inducer, and only the strain contain-
ing pEW72 (WT L27) grew in the presence of arsenite
(Fig. 1B). This demonstrates that not only is L27 cleav-
age essential but it must also be tightly regulated, since
the ‘pre-cleaved’ variant failed to complement. The
released peptide may yet have some role in cellular
processes, but that role is insufficient to promote S. aur-
eus growth without regulated L27 cleavage. These
results confirm that L27 cleavage by Prp is an obligatory
step for S. aureus viability, and validates Prp as a poten-
tial new target for antibiotics. We have accordingly
undertaken further functional characterization of this
important protease.
Prp purification and assay for enzymatic activity
To purify Prp for assessment of substrate binding and
catalysis, and to facilitate the search for inhibitors, we
developed a high throughput-capable continuous fluo-
rescent assay that monitors Prp activity in the presence
of a quenched fluorescent peptide containing the
cleavage motif: 2-aminobenzoic acid-KLNLQFFASKK-
dinitrophenol. When the substrate is cleaved, the N-
terminal fluorophore 2-aminobenzoic acid (2-Abz) is
released from its C-terminal quenching partner dinitro-
phenol (Dnp), resulting in fluorescence at the emission
wavelength 414 nm upon excitation at 325 nm.
Prp was purified as a fusion protein with an N-
terminal His6-SUMO moiety. The His6-SUMO tag was
specifically removed using His6-Ulp1 protease, the mix-
ture was dialyzed to remove imidazole, and untagged
Prp was purified away from the His6-Ulp1 and the His6-
SUMO tag by passage over a second nickel-NTA col-
umn (Supporting Information Figure S1). The dimer
present in the S. aureus Prp crystal structure (PDB
2P92, revised to 4PEO; Chirgadze et al., 2015) was veri-
fied in vitro using a size-exclusion column (Supporting
Information Figure S2).
Assay conditions were tested for efficiency of cleavage,
and the optimal pH, ionic strength and concentrations of
EDTA and DTT were determined. The enzyme displayed
optimal activity at pH 7.0, was relatively insensitive to
EDTA concentration over a range from 0 to 5 mM or DTT
over a range from 0 to 6 mM, and was slightly inhibited by
the addition of NaCl (up to 600 mM). Standardized assays
were performed at pH 7.0 in sodium phosphate buffer with
1.5 mM DTT and 2.35 mM EDTA. Prp readily reacts with
Ellman’s reagent (5,50-dithiobis(2-nitrobenzoic acid))
under non-denaturing conditions and is inhibited by a
chloromethylketone-containing substrate peptide, Ac-
KLNLQFF-CMK, consistent with its identification as a cys-
teine protease.
Raw assay data were corrected for background with
respect to no-enzyme blank reactions and then con-
verted to concentration of substrate cleaved using a
standard curve generated by cleavage of the substrate
with trypsin (Supporting Information Figure S3A). Cleav-
age of the fluorescent peptide by Prp was shown to pro-
gress to completion by comparing final fluorescence
values produced by Prp and trypsin (Supporting Infor-
mation Figure S3B). The maximum velocity for cleavage
of the fluorogenic substrate was determined to be
1.9606 0.060 nM/s, the Km was 0.182460.0280 lM,
the turnover number (kcat) was 0.04586 0.0014 s
21 and
the specificity constant (kcat/Km) was 0.25116 0.0393
lM21s21 (Fig. 2). The Km of Prp for its quenched fluo-
rescent substrate is quite low when compared to other
motif directed cysteine proteases. For example, the viral
nuclear inclusion A proteases like that of Tobacco Etch
Virus, and the picornaviral 3C endopeptidases, have
minimum Km values of 69 to 5uM, respectively, for fluo-
rescent peptide substrates (BRENDA database; Schom-
burg et al., 2002).
To explore the feasibility of utilizing peptide derivatives
as a scaffold for drug design, we examined the ability of
peptides of various lengths containing the substrate
cleavage motif to competitively inhibit enzymatic activity.
Using 0.2 lM fluorogenic substrate and 21.38 nM
enzyme (calculated as a dimer), a non-fluorescent pep-
tide with the same 11 amino acid sequence as the fluo-
rogenic substrate gave 50% inhibition at a concentration
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between 0.8 and 1 mM. Shorter peptides were much
poorer inhibitors, and due to their low solubility we were
unable to perform titrations to determine their Ki values.
As an alternative, competitive peptides were assayed at
0.8 mM (the concentration that gave  50% inhibition
with the 11-mer) and the initial velocity for each reaction
was used to calculate the percent inhibition with respect
to a fluorogenic-peptide-only (no inhibitor) control. Inhibi-
tion by peptides derived from the L27 cleavage
sequence dropped off rapidly with decreasing length,
suggestive of a requirement for extended peptide recog-
nition (Table 1; Supporting Information Figure S4).
Cleavage of alternative peptide substrates derived from
the phage 80a capsid protein (CP) cleavage motif
(Poliakov et al., 2008) was also consistent with this over-
all trend. A 13-mer corresponding to the CP N-terminal
cleavage motif gave increased inhibition, while a CP 11-
mer yielded results similar to the 11-mer from L27
(Table 1; Supporting Information Figure S4).
Molecular modeling of the active site and peptide
docking
S. aureus Prp is a 23.4 kDa dimer composed of two
identical chains of 106 amino acids (2P92, revised to
4PEO; Chirgadze et al., 2015). Two additional structures
of Prp from bacteria encoding L27 as a pro-protein were
available in the PDB, both also obtained from crystallo-
graphic consortia. These included homologs from S.
pneumoniae (2IDL, unpublished) and Streptococcus
mutans (2G0I, unpublished). A striking feature of these
structures is their apparent lack of catalytic capacity.
The catalytic residues must at some point be solvent
exposed to accept substrate, and the His and Cys resi-
dues must face each other in such a way that the His
can abstract a proton from the sulfhydryl group of the
Cys. None of these structures had both of these fea-
tures. The S. aureus Prp structure (2P92), on which our
model is based, is missing part of a flexible loop that
contains the active site histidine in chain A (see Fig.
3A). A model of Prp docked with its substrate is needed
in order to better understand the nature of the catalytic
center and binding mechanism of this highly specific
motif-directed protease.
In cysteine protease catalysis, nucleophilic attack on
the carbonyl carbon in the scissile bond of the substrate
is achieved via a catalytic dyad, His and Cys, or in
some cases a catalytic triad, His, Cys and Asp (or Asn)
(Rawlings and Barrett, 1994). In addition to the con-
served Cys and His residues, almost all members of the
Prp family contain an Asp or Asn at position 31 (all
numbering is with respect to S. aureus Prp), three resi-
dues prior to the catalytic Cys, raising the formal possi-
bility of a catalytic triad in many Prp homologs. The
requirements for catalysis in cysteine proteases noted
above informed the structural modeling of the Prp active
site.
To create the model, chain B and all the co-
crystallizing waters were deleted from 2P92 so that loop
refinement could be performed on monomer chain A.
The modeled regions are indicated in Fig. 3A. The loop
from Gly 21 to Asp 31 was restored and refined into a
pro-catalytic conformation. The only catalytic conforma-
tion of this loop that seemed plausible was one that
resulted in a catalytic dyad comprised of Cys 34 and
His 22. Asp 31 remains near the catalytic center, but it
could not be oriented in such a way that it could act as
a general base to polarize His 22.
The newly modeled Prp chain A was dimerized by
duplication, followed by alignment of the copied chain
Table 1. Inhibition of Prp activity by competitive peptides.
Competitive peptide
Percent inhibition
(Mean6SD)
L27 11mer
Ac-KLNLQFFASKK-Am
396 5
L27 10mer
Ac-LNLQFFASKK-Am
256 8
L27 8mer
Ac-NLQFFASK-Am
206 7
L27 6mer
Ac-QFFASK-Am
196 8
CP 13mer
Ac-KLKLNLQHFASNN-Am
636 8
CP 11mer
Ac-KLNLQHFASNN-Am
326 10
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Fig. 2. Michaelis-Menten plot of Prp kinetics.
The average initial velocity at each substrate concentration is
plotted. Based on fits to non-linear regression equations for
Michaelis-Menten kinetics and kcat, the vmax was 1.9660.06 nM/s,
the Km was 0.186 0.03 mM, kcat was 0.056 0.00 s
21 and the
specificity constant (kcat/Km) was 0.256 0.04 mM
21s21.
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with chain B of 2P92 to form a dimer with twofold rota-
tional symmetry. The catalytic pair was ionized to repre-
sent their state prior to nucleophilic attack and formation
of a covalent intermediate with substrate. Binding of
peptide substrate very likely occurs in the cleft between
the pair of a helices and the b-sheet of each monomer
structure, where the active site residues lie. Access to
this site required remodeling of a small loop consisting
of residues 62-65 (see Fig. 3A). A 7 amino acid peptide
fragment with the substrate cleavage motif, acetyl (Ac)-
Fig. 3. Prp modeled and docked with a substrate peptide.
A. Alignment of S. aureus Prp with the homologs from S. mutans and S. pneumoniae for which crystal structures have also been reported.
Identical residues are highlighted in black, similar residues in gray. Conserved residues Gly 21, Asp 31 and Ser 38 surrounding the catalytic
center are noted with black circles and the catalytic pair His 22 and Cys 34 are marked with red circles. The secondary structure elements
from the crystal structure of S. aureus Prp are shown above the alignment. The dashed line indicates the region that was absent in the crystal
structure, and the red bars indicate the two regions that were modeled in this study. PDB accession numbers: S. aureus (2P92/4PEO), S.
mutans (2G0I), S. pneumoniae (2IDL). Amino acid sequences were aligned using MUSCLE and formatted in BOXSHADE through the Mobyle
portal (Neron et al., 2009).
B. Surface map of the Prp dimer and docked substrate Ac-NLQFFAS-Am. The catalytic pair residues are labeled and colored according to
atomic convention (sulfur in yellow, oxygen in red, nitrogen in blue and hydrogen here in teal). Prp chain A is depicted in silver, chain B is in
gold and the peptide substrate is shown in copper. In this model, the flexible loop that did not crystallize in PDB ID 2P92/4PEO is arranged in
an arc above the active site. The substrate appears to associate with both chains of the enzyme.
C. Atomic model of the Prp catalytic site. Prp chain B is in gold, chain A is silver with conserved labeled residues shown in atomic convention
colors as above, with carbon shown in graphite and hydrogen in white. The peptide substrate Ac-NLQFFAS-Am is pictured as a ball and stick
model with a copper backbone. In this depiction only the substrate residues FFAS-Am are visible (P2-P2’). The nucleophile (thiolate on Cys
34) is positioned to attack the carbonyl carbon of the scissile bond between P1 Phe and P1’ Ala on the substrate peptide (dotted line). The
imidazolium group of His 22 is shown here p-p stacking with the phenyl group of the P1 Phe and, owing to its flexibility provided by Gly 21
(not visible), is positioned correctly to have abstracted a proton from Cys 34. The conserved hydroxyl group of Ser 38 is thought to provide a
hydrogen bonding partner for the amide group between the P2 and P1 Phe residues. The role of Asp 31 is not clear in this model; its side
chain protrudes near the catalytic site but appears to contact only solvent.
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NLQFFAS-amide (Am), was docked into this model
such that the carbonyl carbon of the scissile bond
was in the closest possible proximity to the Cys 34
thiolate ion. The 7-mer was the largest peptide that
could be docked due to accuracy constraints on free
peptide length. Residues Met 1, Leu 2, Lys 3 and
Leu 4 from the full L27 cleavage motif do not appear
in the model, although Leu 4 is quite conserved. After
docking and molecular dynamics (MD) simulations the
two phenyl side chains of the peptide substrate fit well
into hydrophobic pockets near the enzyme catalytic
center. The result is depicted in Fig. 3B and C, with
alternate views including a ribbon model that demon-
strates the flexible loop clearly in Supporting Informa-
tion Figure S5 A, and hydrophobicity maps of the Prp
dimer alone and bound to substrate (Supporting Infor-
mation Figure S5 B and C).
This model predicts the importance of some con-
served Prp residues, but is ambiguous regarding others.
The side chain of the Ser 38 residue on Prp, which is
universally conserved as a serine or threonine among
all Prp homologs, is a likely hydrogen bonding partner
for the peptide nitrogen between P2 Phe and P1 Phe in
the substrate backbone and may serve to orient the
neighboring scissile bond for catalysis. The side chain
of Asp 31 does not seem to interact with anything
directly, but its conservation in more closely related Prp
homologs suggests an important function, perhaps
related to full-length substrate binding. The conserved
location of His 22 in a flexible loop downstream of Gly
21 is consistent with changes in conformation around
the active site upon substrate binding to adopt a cata-
lytic conformation. Thus, the flexibility imposed by Gly
21 might be instrumental in the sequence specificity of
Prp. The model suggests a possible pi-pi stacking inter-
action of catalytic His 22 on the enzyme with the P1
Phe on the substrate (Fig. 3C). Given the inherent flexi-
bility of the loop, this stacking interaction could confer
stability to the active conformation of the enzyme only in
the presence of its appropriate substrate, thereby linking
enzyme activity directly with sequence specificity.
Prp mutants
Based on structural predictions from the model and
sequence conservation data, mutations were made in
the catalytic cysteine (C34), the catalytic histidine (H22),
the conserved and possibly hinge-like glycine (G21), the
conserved aspartic acid (D31) and the conserved serine
(S38). Each of these residues was replaced by alanine
with the exception of C34, which was changed to serine.
Prp C34S is an isosteric mutant that had already been
characterized as being able to bind but not cleave
tagged L27 (Wall et al., 2015). The D31A mutation
was made to formally test whether that conserved
aspartic acid has a role as part of a catalytic triad,
even though this model does not predict one. The
H22A and C34S catalytic site mutants were expected
to abrogate Prp activity while the S38A mutation was
expected to affect substrate binding. The G21A hinge
mutation was predicted to reduce the flexibility of the
loop containing the catalytic histidine, affecting cataly-
sis, substrate binding or both.
Activity of selected Prp point mutants
Wild-type Prp and the mutants C34S, G21A, H22A,
D31A and S38A were assayed at 21.38 nM with 2.0 lM
fluorogenic substrate. Figure 4A shows that none of the
mutants had any measureable activity at this concentra-
tion. To determine whether higher concentrations of
mutant enzyme would produce any measureable activity,
213.8 nM of each enzyme was tested with 2.0 lM sub-
strate. Of these reactions, only the S38A mutant had
slight activity, displaying just 2.16 0.2% activity relative
to the wild-type enzyme. All of the mutations made in
Prp were severely detrimental to substrate binding, catal-
ysis or both.
To help distinguish between defects in binding and
catalysis, we examined the mutants for substrate bind-
ing via fluorescence polarization. This assay measures
the enzyme’s ability to bind and slow the rotation of a
fluorescent substrate. Peptide 2-Abz-KLNLQFFASKK-
Am (identical to the enzymatic assay substrate except
for the lack of a Dnp quencher) was added at 3 lM to
various molar concentration ratios of Prp. The isosteric
Cys to Ser mutation was expected to eliminate catalytic
activity but not substrate binding, and the C34S mutant
did yield maximum polarization. All of the other mutants
showed reductions in polarization, ranging from moder-
ate in the case of S38A to drastic in the case of G21A
(Fig. 4B). These data suggest that the main factor caus-
ing the inactivity of these mutants is their inability to
bind the peptide substrate. Prp H22A, while mutant at a
catalytic residue, demonstrates a deficiency in binding
as well when compared to the C34S mutation. This
could be due to loss of the hypothesized pi-pi stacking
interaction with the P1 Phe of the substrate, as dis-
cussed above. The S38A mutant retains a small amount
of activity, which is consistent with its ability to bind
slightly better than the other non-catalytic mutants,
D31A and G21A. The severe loss of binding and lack of
catalytic activity in the G21A mutant provides support
for the hypothesis that the conserved glycine is a hinge
that allows the flexible loop to adopt its bound catalytic
conformation in the presence of the correct substrate.
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Discussion
This work confirms the presence of a novel essential
pathway in S. aureus for proteolytic processing of a pre-
cursor of ribosomal protein L27 to its functional mature
form. This pathway is also likely to be essential in all Fir-
micutes, Synergistetes, Fusobacteria and related bacte-
ria, including some pathogenic Tenericutes. Importantly,
this L27 processing step is apparently regulated,
because pre-cleaved L27 D 2-9 cannot complement an
L27 deletion. Edman degradation confirms that the
expression of the pre-cleaved L27 mutant produces a
protein identical to that found in mature ribosomes (no
retained N-formyl Met), indicating that its normal func-
tion of tRNA stabilization should be intact. The un-
cleavable mutant was not expected to complement an
L27 deletion because retention of the N-terminal
extension was postulated to interfere with the activity of
the PTC. Previous studies have shown that uncleaved
L27 is associated with 50S ribosomal subunit precur-
sors, as is mutant Prp that is cleavage-defective (Wall
et al., 2015). We have not been able to experimentally
address whether ‘pre-cleaved’ L27 is assembled into
ribosomes, due to the lethality of the L27 D 2-9 muta-
tion. Thus, we cannot at this point distinguish whether
the function of this cleavage process is related to ribo-
some biogenesis, regulation of translation or perhaps
both. However, an attractive hypothesis consistent with
the current evidence is that Prp serves as a chaperone for
L27 assembly. The ribosome is understood to have myr-
iad chaperones involved during its construction, many of
which are enzymes (Wilson and Nierhaus, 2007; Shajani
et al., 2011; Goto et al., 2013). It could be that cleavage
Fig. 4. Analysis of Prp active-site
mutants.
A. Enzymatic activity. The average
percent activity for each mutant is
shown relative to the wild-type enzyme.
Each enzyme was assayed at a
concentration of 21.4 nM (dimer), as
described in Experimental Procedures.
Error bars indicate one standard
deviation; n 3.
B. Substrate binding. Substrate binding
as measured by fluorescence
polarization is shown for each of the Prp
point mutants, at differing molar ratios of
mutant enzyme to 3 mM substrate. Error
bars represent 95% CI, n54. The grey
bar summarizes the range of
background fluorescence from each of
the individual experiments.
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occurs after the L27 pro-protein has been incorporated
into a large ribosomal subunit precursor in order to disen-
gage Prp from the complex. This would also be consistent
with the observed low turnover rate for this enzyme.
Regardless of the biological role of L27 precursor cleav-
age, it is clear that the action of Prp provides an important
new drug target in highly drug resistant pathogens, and
Prp characterization is a necessary foundation for the
possible development of new antimicrobials.
S. aureus Prp is the prototype of its novel structural
clade and presents opportunities to understand the bio-
chemistry of an entirely new group of cysteine proteases.
The Prp homolog structures from S. pneumoniae and S.
mutans (PDB IDs 2IDL and 2G0I respectively) show a
high degree of structural conservation despite low
sequence identity - no more than 47% (see Fig. 3A).
Homology modeling of related Prp sequences of unknown
structure is consistent with these observed structures.
None of the existing crystal structures, however, is in a
conformation that would allow catalytic activity – the
flexible loop that contains the catalytic His is either miss-
ing or deformed in such a way that the imidazole group of
the His cannot interact with the thiol group of the Cys.
Therefore the model of S. aureus Prp with substrate
depicted here indicates certain important structure-
function relationships of conserved residues in the Prp
family.
The catalytic Cys replacement with isosteric Ser was
made originally to test the possibility that Ser hydroxyl
could substitute as a catalytic nucleophile in this prote-
ase. This is not the case; the enzyme is catalytically
inactive although it still binds substrate (Wall et al.,
2015). The C34S mutant was therefore used as a model
for maximum binding in the fluorescence polarization
assay. The other member of the catalytic pair, His 22, is
suggested by the model to play a dual role in catalysis
and binding, based on an apparent pi-pi stacking inter-
action with the substrate P1 Phe. Enzymatic and fluo-
rescence polarization data are consistent with this
prediction, showing reduced binding in addition to a lack
of activity. Both the modeling and the existing crystal
structures indicate that this residue is located on a
dynamic, flexible loop, possibly only interacting with Cys
34 in the presence of bound substrate. The adjacent
Gly 21 appears to play a critical role in substrate bind-
ing, and our data provide support for the role of this res-
idue as a hinge involved in correct positioning of the
flexible loop.
The S38A mutant showed slight activity (2.060.2%)
relative to wild-type when both were assayed at a higher
enzyme concentration. This is correlated with its ability
to bind and polarize the fluorescent substrate better
than the other mutants tested, aside from C34S. In the
model, this residue supports substrate binding in a non-
sequence specific manner, interacting only with the
backbone amide nitrogen between the P2 and P1 resi-
dues. Ser 38 thus appears to make a significant contri-
bution to enzymatic activity via substrate stabilization.
The role of conserved Asp 31 is not well understood – it
resides one rung of an alpha helix (5.4 A˚) above Cys 34,
permanently ensuring proximity to that residue and not to
His 22, making it seem unlikely that Asp 31 serves as a
general base to ionize His 22. These observations may
indicate that Asp 31 is involved in full-length substrate
binding or organization of the flexible loop to facilitate
catalysis. The substrate peptide Ac-NLQFFAS-Am con-
tains a highly conserved P3 Gln that in this model does
not appear to bind anything on the enzyme directly, and
points outward into solvent. It is possible that the P3 Gln
could interact with the conserved Asp 31 or other residues
on the enzyme if the flexible loop draped over and became
ordered around substrate.
Loop flexibility reduction upon substrate binding has
precedent in other site-specific cysteine proteases. NMR
studies of staphylococcal cysteine transpeptidase sor-
tase A demonstrate that the b6/b7 loop, which is disor-
dered in the apostructure, becomes immobile upon
substrate peptide binding, forming a helix that stabilizes
the enzyme-substrate interaction (Suree et al., 2009).
Previous work demonstrated that mutations of this loop
significantly impaired enzymatic activity and changed
substrate specificity (Bentley et al., 2007; Bentley et al.,
2008). Our results suggest that conserved flexibility of
the loop above the catalytic center could be instrumental
in substrate binding and stabilization in Prp as well.
Another notable feature in the model is a large hydro-
phobic patch that extends below the catalytic center and
includes the region of postulated substrate binding (Sup-
porting Information Figures S5 B and C). The observed
failure of shorter peptides to compete with longer sub-
strates is consistent with a requirement for extended
substrate recognition. An obvious question regarding the
model presented here is how a full-length substrate
might interact with Prp. Based on the crystal structure,
Chirgadze et al. (2015) proposed a ‘sandwich’ interac-
tion involving L21, Prp and L27. They noted the nega-
tive residues distributed over the exterior of Prp and
suggested that they could serve as points of interaction
with the positively-charged ribosomal proteins encoded
in the same operon. At present, our model does not
indicate a purpose for this enzyme’s low isoelectric
point, leaving the formal possibility of a closer associa-
tion with the C-terminal region of L27. However, the
pseudo two-fold rotational symmetry of Prp suggests
that binding to both L21 and L27 at the same time is
improbable, and L21 lacks the cleavage motif. S. aureus
Prp is also known to cleave substrates that are not as
small and positive as L27 – phage 80a scaffold and CP
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both have an isoelectric point of 4.9, and are 23 and 37
kDa respectively.
The model presented in this work does not depict the
orientation of substrate residues past the P2’ serine. In
fact, the amidated C-terminus of that residue seems to
run directly and improbably into Prp density. The first
forty residues of L27 are known to be highly flexible,
only crystallizing in certain full ribosome structures
(Wang et al., 2004; Voorhees et al., 2009; Polikanov
et al., 2014). The long N-arm of L27 contains conserved
glycines that could theoretically allow it to loop sharply.
It is also possible that the large flexible loop in Prp is
moved to one side during catalysis and forms a channel
that accommodates the residues after the cleavage
motif leading to the structured portion of L27. The
amount of flexibility around the catalytic center makes it
very difficult to understand how or where the enzyme
interacts with the C-terminal regions of any substrate.
There simply are not good predictions for the orientation
of a ten residue loop around a substrate docked in silico,
or possible interactions with the corresponding loop on
the other monomer. A co-structure of Prp with substrate
or a substrate analog of sufficient length is required to
shed more light on this interaction.
Site-specific cysteine proteases have been studied as
drug targets in many organisms, especially in relation to
viral polyprotein processing and eukaryotic autophagy-
related processes. There is precedent for smaller ‘drug-
like’ versions of the peptide cleavage motif working as
competitive inhibitors for enzymes like caspase-1 (Mar-
golin et al., 1997). However, the Turnip Mosaic Virus
nuclear inclusion A (TuMV NIa) protease was unable to
cleave smaller substrates, only cleaving peptides of at
least six amino acids in length (Yoon et al., 2000). Simi-
larly, shorter versions of the L27 cleavage motif failed to
competitively inhibit Prp (Table 1), suggesting that small
peptide mimetics are likely an ineffective route to anti-
Prp drug design. The assay we have developed will
allow high throughput screening of libraries to identify
compounds that may inhibit by mechanisms other than
competitive binding.
Prp cleavage was previously implicated in another
system, also involving macromolecular assembly - cap-
sid morphogenesis of staphylococcal phage 80a. At
some point before or during procapsid formation, both
the phage capsid and scaffold proteins are cleaved at a
similar conserved motif (Poliakov et al., 2008). Co-
expression of capsid and scaffold proteins without the
N-terminal motif results in dysregulated assembly of
capsomers into sheets or polyheads (Spilman et al.,
2012). These data suggest that Prp targets substrates
involved in very large and complex macromolecular
assemblies – ribosomes and phage capsids, some of
the oldest and most conserved bacterial or viral
structures. It is possible that Prp has a slightly different
role in these scenarios, but it also seems likely these
complex assemblies have in common the requirement of
some form of regulation during their formation, again
suggestive of a role as a chaperone for Prp.
This work validates Prp as a novel drug target. We
present a model that provides insight into substrate
binding and catalysis by this new clade of sequence-
specific cysteine proteases. These results suggest pos-
sible avenues for the development of new antibiotics
against major drug resistant pathogens that contain Prp
and the L27 N-terminal extension, including Clostridia,
Staphylococci, Streptococci and Enterococci.
Experimental procedures
Bacterial culture
Strains and plasmids used in this study are listed in Sup-
porting Information Table S1. All S. aureus strains are
derivatives of the phage-cured, restriction-defective strain
RN4220 (Kreiswirth et al., 1983). S. aureus strains were
grown in Trypticase Soy Broth or Brain Heart Infusion at
378C. Antibiotics used with S. aureus strains included tetra-
cycline (2 mg/mL), erythromycin (5 mg/ml), chloramphenicol
(15 mg/mL), spectinomycin (250 mg/mL) and kanamycin (30
mg/mL). E. coli strains were cultured in Luria-Bertani (LB)
broth or on LB agar plates supplemented with ampicillin
(100 mg/ml) and/or chloramphenicol (30 mg/ml), as required,
and grown at 378C overnight. Liquid cultures were grown
on an orbital shaker at 200 rpm. For induction of regulated
promoters, IPTG was used at 1 mM and NaAsO2 at 5 mM.
For large scale expression, E. coli strains containing IPTG-
inducible promoters were auto-induced using lactose-
containing media.
DNA manipulation
Polymerase chain reactions were performed using Pfu Ultra
II polymerase (Agilent). Primers used in this study are listed
in Supporting Information Table S2. PCR products were
purified using the NucleospinVR Gel and PCR Clean-up Kit
(Macherey-Nagel; D€uren, Germany) according to manufac-
turer’s instructions. Cloning reactions were performed using
an In-FusionVR HD Cloning Kit (Clontech Laboratories;
Mountain View, CA) or by standard ligation with T4 ligase.
Plasmids were introduced to S. aureus by electroporation.
Strain creation
The S. aureus expression strain SA178RI carries a T7 RNA
polymerase expression cassette under lac operator control.
The plasmid used for T7 expression in SA178RI was
pG164, an E. coli-S. aureus shuttle vector carrying the T7
late promoter into which a lac operator, a multiple cloning
site, an optimized gram-positive ribosome binding site, and
a constitutively expressed copy of the lac repressor gene
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were introduced (D’Elia et al., 2006). The mutant alleles
were created using Gibson assembly of overlapping pieces
of DNA that contained the desired nucleotide changes in
the manipulated 15 base pair (bp) overlap regions. Plas-
mids were isolated from Stellar E. coli (Clontech-Takara) for
sequencing and transformation of the appropriate S. aureus
or E. coli strain. When replacement of S. aureus L27 with a
spectinomycin resistance cassette was required, the mutant
allele was exchanged into the S. aureus chromosome of
strain ST256 using the shuttle plasmid pMAD as described
previously (Arnaud et al., 2004), with the addition of 1 mM
IPTG to ensure expression of plasmid-encoded L27.
Edman degradation
Ni-NTA purified L27 D 2-9 His6 protein samples were
loaded onto a 16.5% Tris-tricine precast gel (Biorad). The
protein was electroblotted to a 0.45 mm PVDF membrane
for 4 hours at 300 mA in a Criterion Tank Blotter (Biorad).
The membrane was stained with Coomassie and the appro-
priate band was marked, coded and sent to the Iowa State
University Protein Facility. There the protein samples on the
membrane were washed six times with deionized water and
loaded onto a 494 Procise Protein Sequencer/140C Ana-
lyzer (Applied Biosystems, Inc).
Recombinant protein overexpression and purification
Hexahistidine-small ubiquitin-related modifier (His6-SUMO)
tagged Prp (or Prp point mutants) and His6-tagged ubiquitin-
like protein-specific protease 1 (Ulp1) were overexpressed in
BL21-CodonPlusTM (DE3)-RIL (Agilent Technologies; Santa
Clara, CA) and ScarabXpress T7 lac (Scarab Genomics;
Madison, WI) E. coli cells respectively. Bacteria were lysed
using an Emulsiflex C3 High Pressure Homogenizer (Avestin;
Ottawa, ON, CA) at approximately 20,000 psi. Lysate was
clarified by centrifugation at 20,000 rpm for 30 minutes at
108C. A nickel affinity column was prepared by adding 10-
20 ml of ProfinityTM IMAC Uncharged Resin (Bio-Rad; Hercu-
les, CA), followed by 5-10 ml of 100 mM nickel sulfate
(NiSO4). The column was washed with 30 ml of wash buffer
(25 mM Tris, pH 8, 300 mM NaCl, 10 mM imidazole) and the
clarified supernatant was added to the column, allowing the
His6-tagged protein to bind the resin. The bound protein was
washed and eluted with 100 ml elution buffer (25 mM Tris,
pH 8, 300 mM NaCl, 110 mM imidazole). The fractions were
then analyzed via SDS-PAGE. The fractions containing the
protein of interest were pooled, sodium azide was added to
0.02% v/v, and the protein was dialyzed versus 50 mM
sodium phosphate buffer, pH 7.5 with 0.02% v/v sodium azide
(and 10% v/v glycerol for Ulp1). To cleave the His6-SUMO
tag from purified and dialyzed His6-SUMO-Prp, His6-tagged
Ulp1 was added in an approximately 1:1 ratio by weight with
His6-SUMO-Prp with 150 mM NaCl at room temperature.
Five microliter samples were taken at t5 0 h, 1 h, 2 h and 3 h
and analyzed for extent of cleavage via SDS-PAGE. After suf-
ficient cleavage, the mixture was purified via nickel affinity
chromatography in the same manner as the tagged protein,
except fraction collection began immediately after the sample
was applied to the column. After dialyzing, the purified,
tagless protein in solution was filter sterilized using a MillexVR
0.22 mm syringe filter (EMD Millipore; Billerica, MA) and the
protein concentration was determined using Bradford reagent
and A280, which gave comparable results. Glycerol was
added to 40% v/v, and one milliliter aliquots were stored at
2208C. Glycerol was eliminated from purified Prp mutants via
buffer exchange during concentration before fluorescence
polarization experiments.
Fast protein liquid chromatography
Fast protein liquid chromatography (FPLC) was performed
on a mixed sample of tagless, wild-type Prp and His6-
tagged Ulp1 using an €AKTAFPLCTM system with UNI-
CORNTM system control software and a 125 ml P-10TM
size-exclusion column (20,000 MWCO; Bio-Rad; Hercules,
CA) equilibrated to 50 mM sodium phosphate buffer, pH
7.5. Five milliliters of Prp:Ulp1 sample was manually
injected onto the column and eluted with 50 mM sodium
phosphate buffer, pH 7.5. Two-milliliter fractions were col-
lected at a flow rate of 1 ml/min while the elution profile
was monitored spectrophotometrically at 280 nm. Peak
fractions were analyzed via SDS-PAGE.
Fluorogenic peptide cleavage assay
Peptides used in this study were purchased from United
Biosystems (Herndon, VA). Stock fluorogenic peptide
(SauL2711) was made by dissolving a small amount of
lyophilized peptide in DMSO. Its concentration was deter-
mined by measuring its absorbance in a 0.1 cm pathlength
quartz cuvette at 325 nm with a Bio-RadVR SmartSpecTM
3000. Aliquots were frozen at 2208C until use. Competi-
tive non-fluorescent peptide substrates used in this study
were resuspended to 1 mM with DMSO. These working
stocks were stored at 2208C until use. Fluorescence
assays were performed using a Tecan InfiniteVR M1000
microplate reader with MagellanTM data analysis software
(M€annedorf, Switzerland) and GreinerVR Bio-One black,
flat-bottomed, chimney well, non-sterile, non-binding, 96-
well microplates (Monroe, NC). The plate reader was set
to read fluorescence intensity at an excitation wavelength
of 325 nm and an emission wavelength of 414 nm with
5 nm bandwidths. Cleavage reactions were read at 8-
second intervals for 10 minutes at ambient temperature.
The plate reader’s gain was optimized at 255 and the Z-
position height was optimized at 20,450 mm. Standardized
assays had final concentrations of 1.5 mM DTT, 2.35 mM
EDTA, 2.53% DMSO, and various concentrations of fluoro-
genic peptide and/or competitive peptide in 50 mM sodium
phosphate buffer, pH 7.0.
Standard curve generation and determination of the
extent of assay completion
To convert the raw values of relative fluorescence units
(RFU) versus time from the assay data to concentration of
fluorogenic substrate cleaved versus time, a standard curve
of RFU versus concentration of fluorogenic substrate
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cleaved by trypsin was prepared (Supporting Information
Figure S3A). Ten microliters of 1 mg/ml trypsin in 50 mM
sodium phosphate buffer, pH 7.5, with 40% glycerol and
0.02% sodium azide was used in the standard cleavage
assay with varying amounts of substrate (0-1.0 mM). A no-
enzyme blank was used to correct for background. The
blank-corrected RFU values from four completed reactions
at each concentration were averaged and the results were
plotted versus the concentration of substrate included in
the reaction. Trypsin was also used in assays to determine
the extent of assay completion by Prp. Identical assays
were performed, cleaving 2 mM substrate with 10 ml of
1 mg/ml trypsin and Prp and the average absolute RFU
values for four completed reactions were compared (Sup-
porting Information Figure S3 B). Both reactions
approached the same RFU values, indicating that both
reactions proceeded to the same extent of completion.
Enzyme activity analysis
Assay data were analyzed using MicrosoftVR ExcelVR 2011
and GraphPad PrismVR (La Jolla, CA). Data were collected
and organized in ExcelVR , then the blank RFU value at each
time point was subtracted from the corresponding time
point of each trial for each assay. The blank-corrected RFU
data were then converted to concentration of substrate
cleaved using the equation of the standard curve (Support-
ing Information Figure S3A) and plotted using a smooth
marked scatter plot. The slope of the initial, linear portion
of each curve (initial velocity) was determined for each
assay.
For measurement of wild type Prp enzyme kinetics, Prp
was used at a final concentration of 21.38 nM (as dimer).
The initial velocities for each substrate concentration were
entered into PrismVR , where the data were analyzed using
non-linear regression fits to the Michaelis-Menten kinetics
and kcat equations (ET constrained to 42.765 nM active
sites; 2 active sites per dimer).
For competition data with competitive-peptide inhibitors,
the percent activity and percent inhibition relative to a no-
inhibitor control were calculated from the initial velocities for
each inhibitor assay. These results were then entered into
PrismVR and analyzed using an ordinary one-way ANOVA,
comparing the mean initial velocity for each inhibitor to that
of the no-inhibitor control. For the Prp active-site mutants,
the percent activity relative to a wild-type control was calcu-
lated from the initial velocities for each mutant. These
results were then entered into PrismVR and analyzed using
an ordinary one-way ANOVA, comparing the mean initial
velocity for each mutant to that of the wild-type enzyme.
Fluorescence polarization
Fluorescence polarization experiments were conducted on
a Flex Station 3 by Molecular Devices (Sunnyvale, CA).
Polarization of the substrate 2-Abz-KLNLQFFASKK-Am
was analyzed at 415 nm. The reactions were formulated
with 3 mM substrate in the presence of inactive Prp mutants
at molar ratios of 1, 2.2, 7.6, 15.2 and 30.3 Prp muta-
nt::substrate. Lower molar ratios of Prp mutants to
fluorescent substrate produced no detectible polarization,
possibly due to sensitivity limits of the polarization reader
utilized in this study.
Molecular modeling
The existing crystal structure of S. aureus Prp (PDB ID:
2P92; now 4PEO) lacks the loop that includes the active
site residue His 22. The PDB file of the incomplete S. aur-
eus Prp/YsxB homolog dimer was read into SYBYL-X ver-
sion 2.1. Modeller version 9.12 (Webb and Sali, 2014) was
used to model the loop that was not present in the crystal
structure. One loop model was created using the loop_mo-
del.py script written by Dr. Hardik Parikh, and the loop was
refined using the loop_refine.py script also written by Dr.
Parikh. Over 200 models were created and read into
SYBYL (Certara, Princeton, NJ), and one was chosen that
contained a favorable His/Cys pro-catalytic conformation.
The four residue loop (residues 62-65) had a closed confor-
mation that partially obscured the active site of the enzyme.
For this reason, the loop_refine.py script was again utilized
to allow the four residue loop to adopt a conformation that
did not obscure the active site. The model with greatest sol-
vent exposure of the catalytic site was chosen. This model
was read into SYBYL, along with the original crystal 2P92
which formed the template for modeling the dimer. This
dimer was read into Gold 5.2, and docking was achieved
using the blocked peptide Acetyl (Ac)-Asn-Leu-Gln-Phe-
Phe-Ala-Ser-Amide (Am). MD simulations were carried out
with the NAMD 2.8 package developed by the Theoretical
and Computational Biophysics Group in the Beckman Insti-
tute for Advanced Science and Technology at the University
of Illinois at Urbana-Champaign (Phillips et al., 2005).
CHARMM (Charmm-27) was used as the force field (MacK-
erell et al., 1998). Prior to simulation, the ionization states
of His residues were checked using PROPKA 3.1 (Olsson
et al., 2011). The analysis of the MD trajectory was done in
VMD (Humphrey et al., 1996).
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